Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03965234 · ClinicalTrials.gov registry record · Phase 1

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

A Phase 1 study of Colorectal Cancer and Metastatic Malignant Neoplasm in the Lung, sponsored by Roswell Park Cancer Institute.

Recruiting
Registry status
Phase 1
Development phase
99
Enrollment target
1
Study location

NCT03965234 is a Phase 1 study of Colorectal Cancer and Metastatic Malignant Neoplasm in the Lung that is actively recruiting participants, run by Roswell Park Cancer Institute. The registered enrollment target is 99 participants, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03965234, a Phase 1 study of Colorectal Cancer and Metastatic Malignant Neoplasm in the Lung, is actively recruiting participants, sponsored by Roswell Park Cancer Institute.

RECRUITING
Registry status
Phase 1
Development phase
99 participants
Enrollment target
1
Study location

Study Summary

This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Pulmonary suffusion may also be useful in avoiding later use of drugs by vein that demonstrate no effect on tumors when delivered locally.

Conditions Studied

Colorectal Cancer Metastatic Malignant Neoplasm in the Lung Metastatic Soft Tissue Sarcoma Resectable Sarcoma Metastatic Bone Sarcoma Metastatic Unresectable Sarcoma

Interventions

  • DRUG Cisplatin
  • PROCEDURE Isolated Chemotherapeutic Lung Perfusion
  • PROCEDURE Metastasectomy

Study Locations (1)

New York

  • Roswell Park Cancer Institute - Buffalo

Trial Details

FieldValue
Enrollment Target 99 participants
Start Date 2020-07-16
Est. Completion 2030-05-25
Phase Phase 1

Sponsor

Roswell Park Cancer Institute

365 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03965234

The ClinicalTrials.gov registry entry for NCT03965234 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 99 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,511-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Roswell Park Cancer Institute, which has 365 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Cisplatin is the first listed.

NCT03965234 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03965234 about?

NCT03965234 is a clinical study titled "Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases". This phase I/II trial studies the side effects of pulmonary suffusion in controlling minimal residual disease in patients with sarcoma or colorectal carcinoma that has spread to the lungs. Pulmonary suffusion is a minimally invasive delivery of chemotherapeutic agents like cisplatin to lung tissues....

What is the current status of trial NCT03965234?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 99 participants. The study started on 2020-07-16. Estimated completion is 2030-05-25.

What conditions does trial NCT03965234 study?

This clinical trial studies the following conditions: Colorectal Cancer, Metastatic Malignant Neoplasm in the Lung, Metastatic Soft Tissue Sarcoma, Resectable Sarcoma, Metastatic Bone Sarcoma.

What interventions are being tested in trial NCT03965234?

The interventions under investigation include: Cisplatin (DRUG), Isolated Chemotherapeutic Lung Perfusion (PROCEDURE), Metastasectomy (PROCEDURE).

Who is sponsoring clinical trial NCT03965234?

This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03965234 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Metastatic Malignant Neoplasm in the Lung

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.